EP08.02-065 Response to Systemic Anti-Cancer Therapy in Uncommon EGFR Mutations

Abstract

Exon 19 deletions, exon 21 L858R and exon 20 insertions represent the most frequent alterations in EGFR mutated non-small cell lung cancer (NSCLC). These alterations now all have approved targeted therapies. In contrast, there is limited data assessing activity of EGFR-directed therapy for uncommon EGFR alterations. We sought to describe clinical outcomes of patients with rare EGFR mutations that received systemic anticancer therapy (SACT) at our institution.